May 12, 2020

X Ray Devices Market Trending Expected to Witness the Highest Growth

The

x-ray devices market

on the basis of healthcare institution types is segmented into private not-for-profit hospitals, private for-profit hospitals, public/government hospitals, health screening centers and clinics and others (non-federal psychiatry and non-federal long term care).

The private not-for-profit hospitals enjoy maximum market share in the U.S. According to the American Hospitals Association, in 2010, the private not-for-profit hospitals held approximately 58% of total hospital beds in the U.S. The general/stationary x-ray devices segment in these hospitals acquired majority of the market share at 78.6% in 2011. However, a rise in the purchase of mobile x-ray devices will be observed over the forecast period owing to the following factors:

  • Low radiation risks associated with mobile x-ray devices
  • Its portable nature enabling use across various departments
  • Rising demand for point of care diagnostics and bedside imaging

X-ray devices market by volume in the U.S. is expected to grow at a sluggish rate during the forecast period on account of the implementation of the Affordable Care Act, 2010. The below text provides a detailed explanation of the effect of the implementation of this act on private not-for-profit hospitals:

  • The U.S. Internal Revenue Service (IRS) grants private not-for-profit status to hospitals that spend a minimum of 3% of their operating revenue on uninsured patients/charity. Statistics suggest that the percentage of revenue dedicated towards charity for these hospitals is low (approximately 3.5%).
  • The implementation of the Affordable Care Act will widen the availability of insurance and therefore will limit the availability of uninsured Americans. As a result of this change, hospitals will lose their not for profit status and so, will be no longer be eligible for tax exemption.

Request Sample Of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1512

In contrast to the trends observed in the U.S. x-ray devices market by healthcare institution type, public/government hospitals in China are expected to lead the market from 2012 to 2018. The volume of x-ray devices sold to government/public hospitals in China was valued at 20,291.9 units in 2011. Improvement in the infrastructure of government/public hospitals as a result of the implementation of 12th 5-year plan will serve the market as a driver. General/stationary x-ray devices held majority of the Chinese government/public hospital market share in 2011. However, its market share is expected to decline by 2018. The drop in its market share is justified by the rapid growth in the mobile x-ray devices segment which acts as an internal substitute for general/stationary x-ray devices.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1512

In terms of usage rate of general/stationary, mobile and c-arm x-ray devices by departments, the market is segmented into thoracic, neuro and spine, emergency response, ICU, dental, orthopedic and abdominal departments. General/stationary x-ray devices market dominates most of these departments in terms of usage rate. However, the common trend observed across all these departments in the U.S., Europe and China x-ray devices market, is the acceleration of growth rate in the mobile x-ray devices segment. High maneuverability and low radiation risks associated with mobile x-ray devices are responsible for this market trend.

C-arm devices are also expected to gain usage rate along the forecast period owing to the rising demand for minimally invasive procedures in thoracic and orthopedic departments. In addition, the introduction of technologically advanced c-arm devices such as the Dental Fluoroscopic Imaging Systems (DFIS) will help this market gain acceptance in the field of dentistry.

More Trending Reports by Transparency Market Research –

https://www.biospace.com/article/pharmacovigilance-market-monitoring-of-drug-safety-leads-to-massive-growth-in-phase-iii-clinical-trial-tmr/